Skip to main content

Table 2 Estimation results from Cox proportional hazard models of mortality from OC and from other causes

From: Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study

Variable Mortality from OC Mortality from other causes
Group size Deaths HR (95% CI) Deaths HR (95% CI)
Year of diagnosis
 1998─2002 115 84 1.00 Ref. 13 1.00 Ref.
 2003─2007 149 106 1.17 (0.86–1.59) 12 1.16 (0.45–2.99)
 2008─2011 157 86 0.97 (0.69–1.37) 9 1.13 (0.39–3.27)
Age at diagnosis (years)
 42─59 59 30 0.67 (0.44–1.04) 1 0.18 (0.02–1.53)
 60─69 132 76 1.00 Ref. 9 1.00 Ref.
 70─79 160 120 1.53 (1.14–2.05) 14 2.49 (1.03–6.05)
 80─92 70 50 2.88 (1.98–4.20) 10 5.40 (1.99–14.65)
Duration of diabetes (years)
 0.5─ < 3 103 61 1.00 Ref. 11 1.00 Ref.
 3─ < 6 100 70 1.31 (0.91–1.90) 3 0.35 (0.09–1.36)
 6─ < 12 148 101 1.15 (0.81–1.63) 11 0.88 (0.34–2.27)
 12─ < 34 70 44 0.98 (0.61–1.57) 9 1.20 (0.42–3.44)
Stage
 Local 52 9 1.00 Ref. 9 1.00 Ref.
 Advanced 330 256 9.05 (4.60–17.82) 19 0.80 (0.32–2.01)
 Unknown 39 11 1.60 (0.66–3.89) 6 1.01 (0.32–3.23)
Pre-diagnostic statin use
 No 235 162 1.00 Ref. 20 1.00 Ref.
 Yes 186 114 0.72 (0.56–0.93) 14 0.66 (0.30–1.43)
Pre-diagnostic ADM group
 Metformin 77 46 1.15 (0.74–1.79) 5 1.85 (0.44–7.73)
 Othera 58 44 1.00 Ref. 4 1.00 Ref.
 Metformin and othera 100 67 1.21 (0.82–1.80) 6 1.19 (0.32–4.38)
 Insulin 82 59 1.49 (0.96–2.30) 7 1.61 (0.42–6.18)
 None 104 60 0.69 (0.46–1.03) 12 1.48 (0.46–4.78)
  1. All HRs were adjusted for the other factors in this table
  2. aother oral antidiabetic medication
  3. OC Ovarian cancer, HR Hazard ratio, 95% CI 95% confidence interval